You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBarbital
Accession NumberDB01483
TypeSmall Molecule
GroupsIllicit
DescriptionA long-acting barbiturate that depresses most metabolic processes at high doses. It is used as a hypnotic and sedative and may induce dependence. Barbital is also used in veterinary practice for central nervous system depression. Barbital is a schedule IV controlled drug.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5WZ53ENE2P
CAS number57-44-3
WeightAverage: 184.1925
Monoisotopic: 184.08479226
Chemical FormulaC8H12N2O3
InChI KeyInChIKey=FTOAOBMCPZCFFF-UHFFFAOYSA-N
InChI
InChI=1S/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13)
IUPAC Name
5,5-diethyl-1,3-diazinane-2,4,6-trione
SMILES
CCC1(CC)C(=O)NC(=O)NC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • 1,3-diazinane
  • Urea
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.955
Blood Brain Barrier+0.9694
Caco-2 permeable-0.6146
P-glycoprotein substrateNon-substrate0.5238
P-glycoprotein inhibitor INon-inhibitor0.7826
P-glycoprotein inhibitor IINon-inhibitor0.9964
Renal organic cation transporterNon-inhibitor0.9395
CYP450 2C9 substrateNon-substrate0.7915
CYP450 2D6 substrateNon-substrate0.9074
CYP450 3A4 substrateNon-substrate0.7823
CYP450 1A2 substrateNon-inhibitor0.896
CYP450 2C9 inhibitorNon-inhibitor0.9436
CYP450 2D6 inhibitorNon-inhibitor0.9586
CYP450 2C19 inhibitorNon-inhibitor0.918
CYP450 3A4 inhibitorNon-inhibitor0.9723
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9847
Ames testAMES toxic0.5531
CarcinogenicityNon-carcinogens0.8532
BiodegradationNot ready biodegradable0.9462
Rat acute toxicity3.5489 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9913
hERG inhibition (predictor II)Non-inhibitor0.9734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point190 °CPhysProp
boiling point250 °C at 2.20E+01 mm HgPhysProp
water solubility7460 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.65HANSCH,C ET AL. (1995)
logS-1.39ADME Research, USCD
pKa8.14 (at 15 °C)KORTUM,G ET AL (1961)
Predicted Properties
PropertyValueSource
Water Solubility3.23 mg/mLALOGPS
logP0.73ALOGPS
logP0.72ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)8.48ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity44.25 m3·mol-1ChemAxon
Polarizability17.59 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.31 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05CA04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Barbital is combined with 7-Nitroindazole.
AcebutololBarbital may increase the hypotensive activities of Acebutolol.
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Barbital.
AcepromazineThe risk or severity of adverse effects can be increased when Barbital is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Barbital is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Barbital.
AcetazolamideBarbital may increase the hypotensive activities of Acetazolamide.
adipiplonThe risk or severity of adverse effects can be increased when Barbital is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Barbital is combined with Agomelatine.
AldesleukinBarbital may increase the hypotensive activities of Aldesleukin.
AlfaxaloneThe risk or severity of adverse effects can be increased when Barbital is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Barbital.
AliskirenBarbital may increase the hypotensive activities of Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Barbital is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Barbital.
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Barbital.
AmilorideBarbital may increase the hypotensive activities of Amiloride.
AmineptineThe metabolism of Amineptine can be increased when combined with Barbital.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Barbital.
AmisulprideThe risk or severity of adverse effects can be increased when Barbital is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Barbital is combined with Amitriptyline.
AmlodipineBarbital may increase the hypotensive activities of Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Barbital.
AmoxapineThe risk or severity of adverse effects can be increased when Barbital is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Barbital is combined with Amperozide.
AmrinoneThe metabolism of Amrinone can be increased when combined with Barbital.
Amyl NitriteBarbital may increase the hypotensive activities of Amyl Nitrite.
ApraclonidineBarbital may increase the hypotensive activities of Apraclonidine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Barbital.
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Barbital.
ArticaineThe risk or severity of adverse effects can be increased when Barbital is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Barbital is combined with Asenapine.
AtenololBarbital may increase the hypotensive activities of Atenolol.
AzaperoneThe risk or severity of adverse effects can be increased when Barbital is combined with Azaperone.
AzelastineBarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Barbital.
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Barbital.
Azilsartan medoxomilBarbital may increase the hypotensive activities of Azilsartan medoxomil.
AzimilideThe metabolism of Azimilide can be increased when combined with Barbital.
BaclofenThe risk or severity of adverse effects can be increased when Barbital is combined with Baclofen.
BarnidipineThe metabolism of Barnidipine can be increased when combined with Barbital.
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Barbital.
BenazeprilBarbital may increase the hypotensive activities of Benazepril.
BendroflumethiazideBarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.
BenidipineThe metabolism of Benidipine can be increased when combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Barbital.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Barbital is combined with Benzyl alcohol.
BepridilThe metabolism of Bepridil can be increased when combined with Barbital.
BetaxololBarbital may increase the hypotensive activities of Betaxolol.
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Barbital.
BisoprololBarbital may increase the hypotensive activities of Bisoprolol.
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Barbital.
BretyliumBarbital may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Barbital is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Barbital.
BrimonidineBarbital may increase the hypotensive activities of Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Barbital is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Barbital is combined with Brotizolam.
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Barbital.
BumetanideBarbital may increase the hypotensive activities of Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Barbital.
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Barbital.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Barbital.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Barbital.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Barbital.
ButacaineThe risk or severity of adverse effects can be increased when Barbital is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Barbital is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Barbital.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Barbital.
CanagliflozinBarbital may increase the hypotensive activities of Canagliflozin.
CandesartanBarbital may increase the hypotensive activities of Candesartan.
CaptoprilBarbital may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Barbital.
CarbinoxamineThe risk or severity of adverse effects can be increased when Barbital is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Barbital is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Barbital is combined with Carisoprodol.
CarteololBarbital may increase the hypotensive activities of Carteolol.
CarvedilolBarbital may increase the hypotensive activities of Carvedilol.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Barbital.
CetirizineThe risk or severity of adverse effects can be increased when Barbital is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Barbital is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Barbital can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Barbital.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Barbital.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Barbital.
ChlorothiazideBarbital may increase the orthostatic hypotensive activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Barbital is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Barbital.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Barbital.
ChlorthalidoneBarbital may increase the orthostatic hypotensive activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Barbital is combined with Chlorzoxazone.
CilazaprilBarbital may increase the hypotensive activities of Cilazapril.
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Barbital.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Barbital.
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Barbital.
CitalopramThe risk or severity of adverse effects can be increased when Barbital is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Barbital is combined with Clemastine.
ClevidipineBarbital may increase the hypotensive activities of Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Barbital is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Barbital is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Barbital is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Barbital is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Clonazepam.
ClonidineBarbital may increase the hypotensive activities of Clonidine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Barbital.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Barbital.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Barbital.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Barbital.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Barbital.
CyclizineThe risk or severity of adverse effects can be increased when Barbital is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Barbital.
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Barbital.
CyproheptadineThe risk or severity of adverse effects can be increased when Barbital is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Barbital is combined with Dantrolene.
DapagliflozinBarbital may increase the hypotensive activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Barbital.
DapoxetineThe risk or severity of adverse effects can be increased when Barbital is combined with Dapoxetine.
DarodipineThe metabolism of Darodipine can be increased when combined with Barbital.
deramciclaneThe risk or severity of adverse effects can be increased when Barbital is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Barbital.
DesipramineThe risk or severity of adverse effects can be increased when Barbital is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Barbital is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Barbital is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Barbital is combined with Dexbrompheniramine.
DexmedetomidineBarbital may increase the hypotensive activities of Dexmedetomidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Barbital.
DextromoramideThe risk or severity of adverse effects can be increased when Barbital is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Barbital.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Barbital.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Barbital.
DiclofenamideBarbital may increase the hypotensive activities of Diclofenamide.
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Barbital.
DifenoxinThe risk or severity of adverse effects can be increased when Barbital is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Barbital is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Barbital.
DihydromorphineThe risk or severity of adverse effects can be increased when Barbital is combined with Dihydromorphine.
DiltiazemBarbital may increase the hypotensive activities of Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Barbital is combined with Dimenhydrinate.
DinutuximabBarbital may increase the hypotensive activities of Dinutuximab.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Barbital.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Barbital.
DipyridamoleBarbital may increase the hypotensive activities of Dipyridamole.
DoramectinThe risk or severity of adverse effects can be increased when Barbital is combined with Doramectin.
DosulepinThe metabolism of Dosulepin can be increased when combined with Barbital.
DotarizineThe metabolism of Dotarizine can be increased when combined with Barbital.
DoxazosinBarbital may increase the hypotensive activities of Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Barbital is combined with Doxepin.
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Barbital.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Barbital.
DoxylamineThe risk or severity of adverse effects can be increased when Barbital is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Barbital is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Barbital.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Barbital.
DrotebanolThe risk or severity of adverse effects can be increased when Barbital is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Barbital.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Barbital.
EcgonineThe risk or severity of adverse effects can be increased when Barbital is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Barbital is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Barbital is combined with Efavirenz.
EfonidipineThe metabolism of Efonidipine can be increased when combined with Barbital.
EmpagliflozinBarbital may increase the hypotensive activities of Empagliflozin.
EnalaprilBarbital may increase the hypotensive activities of Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Barbital.
EntacaponeThe risk or severity of adverse effects can be increased when Barbital is combined with Entacapone.
EperisoneThe metabolism of Eperisone can be increased when combined with Barbital.
EplerenoneBarbital may increase the hypotensive activities of Eplerenone.
EprosartanBarbital may increase the hypotensive activities of Eprosartan.
EscitalopramThe risk or severity of adverse effects can be increased when Barbital is combined with Escitalopram.
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Barbital.
EsmololBarbital may increase the hypotensive activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Barbital.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Barbital.
Etacrynic acidBarbital may increase the hypotensive activities of Etacrynic acid.
EthanolBarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Barbital.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Barbital.
EthosuximideThe risk or severity of adverse effects can be increased when Barbital is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Barbital is combined with Ethotoin.
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Barbital.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Barbital is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Barbital is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Barbital.
EtidocaineThe risk or severity of adverse effects can be increased when Barbital is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Barbital is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Barbital is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Barbital.
EtoperidoneThe risk or severity of adverse effects can be increased when Barbital is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Barbital is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Barbital is combined with Ezogabine.
FelbamateThe serum concentration of Barbital can be increased when it is combined with Felbamate.
FelbamateThe risk or severity of adverse effects can be increased when Barbital is combined with Felbamate.
FelodipineBarbital may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Barbital.
FendilineThe metabolism of Fendiline can be increased when combined with Barbital.
FenfluramineThe risk or severity of adverse effects can be increased when Barbital is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Barbital.
FexofenadineThe risk or severity of adverse effects can be increased when Barbital is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Barbital is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Fludiazepam.
FlunarizineThe metabolism of Flunarizine can be increased when combined with Barbital.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Barbital.
FlunitrazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Barbital is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Barbital.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Barbital.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Barbital.
FluspirileneThe risk or severity of adverse effects can be increased when Barbital is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Barbital is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Barbital is combined with Fluvoxamine.
FosinoprilBarbital may increase the hypotensive activities of Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Barbital is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Barbital is combined with Fospropofol.
FurosemideBarbital may increase the hypotensive activities of Furosemide.
GabapentinThe metabolism of Gabapentin can be increased when combined with Barbital.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Barbital.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Barbital is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Barbital.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Barbital.
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Barbital.
GuanfacineBarbital may increase the hypotensive activities of Guanfacine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Barbital.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Barbital.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Barbital.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Barbital.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Barbital.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Barbital.
HydralazineBarbital may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideBarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Barbital.
HydroflumethiazideBarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Barbital.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Barbital.
HydroxyzineThe risk or severity of adverse effects can be increased when Barbital is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Barbital is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Barbital is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Barbital is combined with Indalpine.
IndapamideBarbital may increase the orthostatic hypotensive activities of Indapamide.
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Barbital.
IrbesartanBarbital may increase the hypotensive activities of Irbesartan.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Barbital.
Isosorbide DinitrateBarbital may increase the hypotensive activities of Isosorbide Dinitrate.
Isosorbide MononitrateBarbital may increase the hypotensive activities of Isosorbide Mononitrate.
IsoxsuprineBarbital may increase the hypotensive activities of Isoxsuprine.
IsradipineBarbital may increase the hypotensive activities of Isradipine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Barbital.
KetazolamThe risk or severity of adverse effects can be increased when Barbital is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Barbital is combined with Ketobemidone.
LabetalolBarbital may increase the hypotensive activities of Labetalol.
LacidipineThe metabolism of Lacidipine can be increased when combined with Barbital.
LamotrigineThe metabolism of Lamotrigine can be increased when combined with Barbital.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Barbital.
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Barbital.
LevetiracetamThe risk or severity of adverse effects can be increased when Barbital is combined with Levetiracetam.
LevobunololBarbital may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Barbital.
LevocabastineThe risk or severity of adverse effects can be increased when Barbital is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Barbital is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Barbital is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Barbital.
LevomilnacipranThe risk or severity of adverse effects can be increased when Barbital is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Barbital.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Barbital.
LisinoprilBarbital may increase the hypotensive activities of Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Barbital.
LofentanilThe risk or severity of adverse effects can be increased when Barbital is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Barbital is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Barbital.
LosartanBarbital may increase the hypotensive activities of Losartan.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Barbital.
Lu AA21004The risk or severity of adverse effects can be increased when Barbital is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Barbital is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Barbital.
Magnesium SulfateThe metabolism of Magnesium Sulfate can be increased when combined with Barbital.
ManidipineThe metabolism of Manidipine can be increased when combined with Barbital.
MannitolBarbital may increase the hypotensive activities of Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Barbital is combined with Maprotiline.
MecamylamineBarbital may increase the hypotensive activities of Mecamylamine.
MeclizineThe risk or severity of adverse effects can be increased when Barbital is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Barbital is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Barbital.
MelperoneThe risk or severity of adverse effects can be increased when Barbital is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Barbital.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Barbital.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Barbital.
MetaxaloneThe risk or severity of adverse effects can be increased when Barbital is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Barbital.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Barbital.
MethapyrileneThe risk or severity of adverse effects can be increased when Barbital is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Barbital is combined with Methaqualone.
MethazolamideBarbital may increase the hypotensive activities of Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Barbital is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Barbital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Barbital.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Barbital.
MethsuximideThe risk or severity of adverse effects can be increased when Barbital is combined with Methsuximide.
MethyclothiazideBarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
MethyldopaBarbital may increase the hypotensive activities of Methyldopa.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Barbital.
MetipranololBarbital may increase the hypotensive activities of Metipranolol.
MetolazoneBarbital may increase the orthostatic hypotensive activities of Metolazone.
MetoprololBarbital may increase the hypotensive activities of Metoprolol.
MetyrosineBarbital may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Barbital.
MibefradilThe metabolism of Mibefradil can be increased when combined with Barbital.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Barbital.
MilnacipranThe risk or severity of adverse effects can be increased when Barbital is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Barbital.
MinoxidilBarbital may increase the hypotensive activities of Minoxidil.
MirtazapineBarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Barbital.
MoexiprilBarbital may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Barbital is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Barbital.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Barbital.
NabiloneThe risk or severity of adverse effects can be increased when Barbital is combined with Nabilone.
NadololBarbital may increase the hypotensive activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Barbital.
NebivololBarbital may increase the hypotensive activities of Nebivolol.
NesiritideBarbital may increase the hypotensive activities of Nesiritide.
NicardipineBarbital may increase the hypotensive activities of Nicardipine.
NifedipineBarbital may increase the hypotensive activities of Nifedipine.
NiguldipineThe metabolism of Niguldipine can be increased when combined with Barbital.
NiludipineThe metabolism of Niludipine can be increased when combined with Barbital.
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Barbital.
NimesulideThe metabolism of Nimesulide can be increased when combined with Barbital.
NimodipineBarbital may increase the hypotensive activities of Nimodipine.
NisoldipineBarbital may increase the hypotensive activities of Nisoldipine.
NitrazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Barbital.
NitroglycerinBarbital may increase the hypotensive activities of Nitroglycerin.
NitroprussideBarbital may increase the hypotensive activities of Nitroprusside.
Nitrous oxideThe risk or severity of adverse effects can be increased when Barbital is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Barbital is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Barbital is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Barbital is combined with Olanzapine.
OlmesartanBarbital may increase the hypotensive activities of Olmesartan.
OlopatadineThe risk or severity of adverse effects can be increased when Barbital is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Barbital.
OpiumThe risk or severity of adverse effects can be increased when Barbital is combined with Opium.
OrphenadrineBarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Barbital.
OsanetantThe risk or severity of adverse effects can be increased when Barbital is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Barbital.
OxprenololThe serum concentration of Oxprenolol can be decreased when it is combined with Barbital.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Barbital.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Barbital.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Barbital.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Barbital.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Barbital.
PapaverineBarbital may increase the hypotensive activities of Papaverine.
ParaldehydeBarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Barbital.
ParoxetineThe risk or severity of adverse effects can be increased when Barbital is combined with Paroxetine.
PenbutololBarbital may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Barbital.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Barbital.
PerampanelThe risk or severity of adverse effects can be increased when Barbital is combined with Perampanel.
PerhexilineThe metabolism of Perhexiline can be increased when combined with Barbital.
PerindoprilBarbital may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Barbital is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Barbital.
PethidineBarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Barbital.
PhenindioneThe metabolism of Phenindione can be increased when combined with Barbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Barbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Barbital is combined with Phenoxyethanol.
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Barbital.
PhenytoinThe risk or severity of adverse effects can be increased when Barbital is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Barbital.
PinaveriumThe metabolism of Pinaverium can be increased when combined with Barbital.
PindololBarbital may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Barbital is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Barbital is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Barbital is combined with Pizotifen.
PolythiazideBarbital may increase the orthostatic hypotensive activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Barbital is combined with Pomalidomide.
PractololThe serum concentration of Practolol can be decreased when it is combined with Barbital.
PramipexoleBarbital may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Barbital is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Prazepam.
PrazosinBarbital may increase the hypotensive activities of Prazosin.
PregabalinThe metabolism of Pregabalin can be increased when combined with Barbital.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Barbital.
PrenylamineThe metabolism of Prenylamine can be increased when combined with Barbital.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Barbital.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Barbital.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Barbital.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Barbital.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Barbital.
PromethazineThe risk or severity of adverse effects can be increased when Barbital is combined with Promethazine.
PropacetamolThe metabolism of Propacetamol can be increased when combined with Barbital.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Barbital.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Barbital.
PropoxycaineThe risk or severity of adverse effects can be increased when Barbital is combined with Propoxycaine.
PropranololBarbital may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Barbital is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Barbital is combined with PSD502.
PyridoxineThe metabolism of Barbital can be increased when combined with Pyridoxine.
QuazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Quazepam.
QuetiapineBarbital may increase the hypotensive activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Barbital.
QuinaprilBarbital may increase the hypotensive activities of Quinapril.
QuinethazoneBarbital may increase the orthostatic hypotensive activities of Quinethazone.
RamelteonThe risk or severity of adverse effects can be increased when Barbital is combined with Ramelteon.
RamiprilBarbital may increase the hypotensive activities of Ramipril.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Barbital.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Barbital.
ReserpineBarbital may increase the hypotensive activities of Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Barbital.
RiociguatBarbital may increase the hypotensive activities of Riociguat.
RisedronateThe metabolism of Risedronate can be increased when combined with Barbital.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Barbital.
RomifidineThe risk or severity of adverse effects can be increased when Barbital is combined with Romifidine.
RopiniroleBarbital may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Barbital.
RotigotineBarbital may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Barbital.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Barbital is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Barbital is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Barbital.
SertindoleThe risk or severity of adverse effects can be increased when Barbital is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Barbital is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Barbital.
Sodium oxybateThe risk or severity of adverse effects can be increased when Barbital is combined with Sodium oxybate.
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Barbital.
SotalolBarbital may increase the hypotensive activities of Sotalol.
SpironolactoneBarbital may increase the hypotensive activities of Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Barbital is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Barbital.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Barbital.
SuvorexantThe risk or severity of adverse effects can be increased when Barbital is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Barbital is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Barbital is combined with Tasimelteon.
TelmisartanBarbital may increase the hypotensive activities of Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Barbital.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Barbital.
TerazosinBarbital may increase the hypotensive activities of Terazosin.
TetrabenazineThe risk or severity of adverse effects can be increased when Barbital is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Barbital is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Barbital is combined with Tetrodotoxin.
ThalidomideBarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Barbital.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Barbital.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Barbital.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Barbital.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Barbital.
ThiothixeneThe risk or severity of adverse effects can be increased when Barbital is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Barbital is combined with Tiagabine.
TianeptineThe metabolism of Tianeptine can be increased when combined with Barbital.
TiletamineThe risk or severity of adverse effects can be increased when Barbital is combined with Tiletamine.
TimololBarbital may increase the hypotensive activities of Timolol.
TizanidineBarbital may increase the hypotensive activities of Tizanidine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Barbital.
TolcaponeThe risk or severity of adverse effects can be increased when Barbital is combined with Tolcapone.
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Barbital.
TopiramateThe risk or severity of adverse effects can be increased when Barbital is combined with Topiramate.
TorasemideBarbital may increase the hypotensive activities of Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Barbital.
TrandolaprilBarbital may increase the hypotensive activities of Trandolapril.
TranilastThe metabolism of Tranilast can be increased when combined with Barbital.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Barbital is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Barbital.
TrazodoneThe risk or severity of adverse effects can be increased when Barbital is combined with Trazodone.
TriamtereneBarbital may increase the hypotensive activities of Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Barbital.
TrichlormethiazideBarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Barbital.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Barbital.
TrimipramineThe risk or severity of adverse effects can be increased when Barbital is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Barbital is combined with Triprolidine.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Barbital.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Barbital.
ValsartanBarbital may increase the hypotensive activities of Valsartan.
VerapamilBarbital may increase the hypotensive activities of Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Barbital is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Barbital is combined with Vilazodone.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Barbital.
VortioxetineThe risk or severity of adverse effects can be increased when Barbital is combined with Vortioxetine.
WarfarinThe metabolism of Warfarin can be increased when combined with Barbital.
XylazineThe risk or severity of adverse effects can be increased when Barbital is combined with Xylazine.
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Barbital.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Barbital.
ZiconotideThe metabolism of Ziconotide can be increased when combined with Barbital.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Barbital.
ZimelidineThe risk or severity of adverse effects can be increased when Barbital is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Barbital.
ZolazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Barbital.
ZonisamideThe risk or severity of adverse effects can be increased when Barbital is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Barbital.
ZotepineThe risk or severity of adverse effects can be increased when Barbital is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Barbital is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ionotropic glutamate receptor activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA2
Uniprot ID:
P42262
Molecular Weight:
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:09 / Updated on August 17, 2016 12:23